Claire L. Langrish - Concepedia

Author

Claire L. Langrish

Principia Biopharma (United States)ORCID

Also Known As

C L LANGRISH, C. Langrish, C.L. Langrish, Claire L Langrish, Claire L. Langrish, Claire Langrish

Publications

7.4K

Citations

H-Index

Concepts

All Affiliations

Principia Biopharma (United States)Sanofi (United States)FX Palo Alto Laboratory Illumina (United States)

About

Claire L. Langrish is an author at Principia Biopharma (United States) specializing in immunology, medicine, and neuroimmunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	509
2	Immunology	3	3	509
3	Allergy	1	1	392
4	Cell Biology	1	1	70
5	Neurology	1	1	47

Claire L. Langrish

Publications

6.7K

Citations

H-Index

Page 1

	Year	Citations
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation Claire L. Langrish, Yi Chen, Wendy M. Blumenschein, The Journal of Experimental Medicine	2005	4K
Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation Craig A. Murphy, Claire L. Langrish, Yi Chen, The Journal of Experimental Medicine	2003	1.6K
IL-25 regulates Th17 function in autoimmune inflammation Melanie A. Kleinschek, Alexander M. Owyang, Barbara Joyce-Shaikh, The Journal of Experimental Medicine InflammationCytokineAutoimmune InflammationAutoimmune DiseaseAllergy	2007	392
Neonatal dendritic cells are intrinsically biased against Th-1 immune responses Claire L. Langrish, Jo Buddle, Adrian J. Thrasher, Clinical & Experimental Immunology	2002	209
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease Claire L. Langrish, J. Michael Bradshaw, Michelle Francesco, The Journal of Immunology	2021	108
Co‐inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity Michael Basler, Michelle Lindström, Jacob LaStant, EMBO Reports Molecular ImmunologyAutoimmune DiseaseAutoantibody ProductionImmune RegulationImmunology	2018	70
Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib) Timothy D. Owens, Ken A. Brameld, Erik Verner, Journal of Medicinal Chemistry	2022	65
Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168) Timothy D. Owens, Patrick F. Smith, Andrew Redfern, Clinical and Translational Science Chemoprevention StrategyTyrosine KinaseImmunologyPharmacotherapyImmunotherapy	2021	47
Cutting Edge: Modulation of Intestinal Autoimmunity and IL-2 Signaling by Sphingosine Kinase 2 Independent of Sphingosine 1-Phosphate Eileen T. Samy, Claas A. Meyer, Patrick Caplazi, The Journal of Immunology	2007	46
PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment <i>via</i> inhibition of macrophage antigen‐1 signalling Jan M. Herter, Andreas Margraf, Stephanie Volmering, British Journal of Pharmacology	2017	23

Page 1